Research: Hearn Brain Tumor Research Center
The Thomas K. Hearn, Jr. Brain Tumor Research Center established several translational brain tumor research priorities, including:
- Discovery and development of new molecular anti-brain tumor therapies and their combination with other treatment modalities (Molecular Therapeutics Group)
- Understanding how radiation or other treatments may cause brain injury and how the improvement in the quality of life of patients undergoing various treatments can be achieved (Modulation of Treatment-induced Brain Injury/Quality of Life Group)
- Introduction of noninvasive means to image both normal brain and brain tumors at cellular and molecular levels, including damage evoked by and response to treatment (Bioanatomic Imaging Group)
- Exploiting preclinical models offered by large animals, e.g., dogs with spontaneous tumors or nonhuman primates (NHPs) for studying cognitive functions (Pre-clinical Models of Disease Group, in continuously growing collaboration with Virginia Tech).